DarioHealth Corp. (DRIO) PT Lowered to $25 at Aegis Capital

Aegis Capital analyst Nathan Weinstein lowered the price target on DarioHealth Corp. (NASDAQ: DRIO) to $25.00 (from $28.00) while maintaining a Buy rating.

Analyst comments: "DarioHealth is undertaking a shift from B2C to B2B2C and appears well-situated to benefit from powerful trends underpinning the increased adoption of DTx solutions for the management of chronic conditions. Further, DarioHealth should benefit from the integration of its several recent acquisitions, and the likely conversion of even more of its new business funnel, ahead. We think there's potential for partnerships in the healthcare sector, and believe that, over time, an increasing number of large pharma and med device companies will commit decisively to a DTx strategy; to the extent they choose to enter the space through a collaboration, DarioHealth could be a logical option. As we see it, new B2B wins, ARR realization, acquisitions, and/or partnership announcements could all serve as catalysts."

You May Also Be Interested In

• Bicara Therapeutics Inc (BCAX) PT Raised to $39 at BTIG
• Rapid7 (RPD) PT Raised to $13 at Stifel
• SandRidge Energy (SD) PT Lowered to $14 at Freedom Broker